隐匿的肌少症:低估非酒精性脂肪性肝炎中肌肉功能障碍的风险与后果
非酒精性脂肪性肝病(NAFLD)是全球最常见的慢性肝病,部分患者可进展为非酒精性脂肪性肝炎(NASH)。肌少症以骨骼肌质量、力量和功能进行性全身性丢失为特征,在终末期肝病患者中可达60%并提示预后不良。本综述探讨肌少症与NASH之间的复杂相互关系、肌少症对NASH患者的影响及肌少症的治疗选择。
要点
- 肌少症是发生NAFLD的新危险因素,在终末期肝病患者中可达60%并提示预后不良。
- 肌少症与NASH相关的病理生理机制可能包括胰岛素抵抗和炎症增加。
- 将骨骼肌视为分泌多种有益肌细胞因子的内分泌器官有助于理解其在脂肪变性中的作用。
核心结论
- 肌少症与NASH之间存在复杂的相互关系,更好地理解其病理生理有助于开发物理和药物治疗干预。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- NAFLD是全球最常见的慢性肝病,多达三分之一的NAFLD患者会发展为NASH,NASH与进展为肝硬化相关并正迅速成为肝移植的主要指征。
- 肌少症在多达60%的终末期肝病患者中可见,并提示预后不良。
- 近期研究显示肌少症是发生NAFLD的新危险因素。
- 肌少症与NASH相关的病理生理机制可能包括胰岛素抵抗和炎症增加;胰岛素抵抗导致甘油三酯在肌肉组织和肝脏中蓄积,并加剧蛋白质分解导致肌肉耗竭;慢性炎症导致肝损伤和纤维化进展,炎症环境也刺激蛋白质分解代谢。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Up to one third of individuals with NAFLD will develop nonalcoholic steatohepatitis (NASH), which is associated with progression to cirrhosis and is rapidly becoming the leading indication for liver transplantation. Sarcopenia is defined as a progressive and generalized loss of skeletal muscle mass, strength, and function. It is observed in up to 60% of patients with end-stage liver disease and portends a poor prognosis. Recent studies have shown that sarcopenia is a novel risk factor for developing NAFLD. Pathophysiological mechanisms relating sarcopenia and NASH may include insulin resistance (IR) and increased inflammation. IR leads to accumulation of triglycerides in both muscle tissue and the liver. It also exacerbates proteolysis and leads to muscle depletion. Chronic inflammation leads to liver injury and progression of fibrosis. The inflammatory milieu also stimulates protein catabolism. Viewing skeletal muscle as an endocrine organ that secretes various salutary myokines may help us understand its role in the development of steatosis. A better understanding of the pathophysiology will aid in developing physical and pharmacological therapeutic interventions. In this review, we will explore the complex inter-relationships between sarcopenia and NASH. We will discuss the impact of sarcopenia in patients with NASH and therapeutic options for the management of sarcopenia. (Hepatology 2017;66:2055-2065).
引用
- Bhanji RA, Narayanan P, Allen AM, et al. Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology. 2017. PMID: 28777879. doi:10.1002/hep.29420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。